Juvenile myoclonic epilepsy (JME), otherwise known as Janz syndrome and impulsive petit mal, is an idiopathic, hereditary, and generalized form of epilepsy. It was first described by Herpin in 1867, later on by Janz and Christian in 1957 as 'impulsive petit mal,' and by Lund in 1975 as JME. Its characteristics are the presence of absence, myoclonic, and generalized tonic-clonic seizures.
JME falls into the classification an idiopathic as well as hereditary (positive family history in approximately 50% of cases) disorder.
Pathophysiology of JME has both idiopathic and hereditary components. The genetics of inheritance is not fully understood, but a multifactorial mechanism is suspected. CACNB4, EFHC1, GABRA1 are some of the genes that carry known associations with JME. Although magnetic resonance imaging (MRI) of the brain is unremarkable in classic JME cases, there are reports of structural defects as a possible cause of JME.
Majority of patients with JME start having seizures between the age group 12 to 18 with a mean age of onset around 15 years. But, the onset can be early or later with an age range between 5-34 years. As mentioned in the introduction, JME is characterized by the presence of absence, myoclonic, and generalized tonic-clonic (GTC) seizures. All patients with JME have myoclonic seizures, 85-90% patients have GTC seizures, and about 20-40% patients have absence seizures.
Myoclonic seizures are the hallmark of this condition and are necessary for the diagnosis of JME. Only occasionally, they will manifest as the only seizure type. They are described as brief, usually bilateral, jerking movements of the arms and sometimes legs with preservation of consciousness. The misdiagnosis of myoclonic seizures is possible as twitches or anxiety/nervousness. Many a time, increasing intensity and frequency of myoclonic jerks in clusters evolve into GTC seizures. GTC seizures usually occur a few months after the onset of myoclonic seizures. Absence seizures are generally the first seizures to manifest in JME. They tend to occur 3 to 5 years before the onset of myoclonic or GTC seizures, sometimes as early as 5 to 6 years of age. The early and isolated occurrence of absence seizures frequently leads to a diagnosis of childhood or juvenile absence epilepsy. Seizures with JME occur 30 minutes to an hour after morning awakening, especially the myoclonic seizures. Usual triggers for JME are sleep deprivation, alcohol intake, emotional stress, anxiety, fatigue. A large proportion (30-40%) of JME patients exhibit photosensitivity and flashing lights, sunlight, TV, and computer can trigger seizures. Photosensitive patients tend to have an earlier onset of seizures.
Physical examination remains normal, and cognition well preserved. Studies suggest an increased prevalence of psychiatric disorders including anxiety, mood disorder, and personality disorders in patients with JME.
History provides most of the clues necessary for a diagnosis of JME. Physical examination is generally unremarkable. An electroencephalogram (EEG) provides supporting evidence for diagnosing JME. An interictal EEG is abnormal in the majority of patients with JME. If the routine EEG is normal, an overnight and sleep deprived EEG is abnormal in almost every patient. The abnormalities are seen mostly during the transition from sleep to awakening. The typical EEG in JME shows diffuse, symmetric, bilateral 4 to 6 hertz (Hz) polyspike and wave discharges with a fronto-central predominance. The background has normal alpha rhythm, and approximately half of patient population will have focal or asymmetric abnormalities. Ictal or continuous EEG recording shows 10-16 Hz polyspike discharges with myoclonic jerks. The spikes correlate with myoclonic jerks. The EEG findings in GTC (low voltage fast activity with spike and wave discharges) and absence seizures (generalized 3 Hz spike and wave discharges) associated with JME are similar to those seen with other epilepsies. Since it is known to be a photosensitive epilepsy, photic stimulation provides enhanced yield on EEG in JME.
If history, examination, and EEG are indicative of JME, imaging (with magnetic resonance imaging-MRI) is usually unnecessary as it tends to be normal. Although, there are reports/studies about structural abnormalities in the cortex and subcortical gray matter in JME patients. There have been reports on JME patients showing abnormalities on electrophysiological tests and advanced imaging techniques such as magnetic resonance spectroscopy (MRS) and positron emission tomography (PET) as well.
JME is relatively easy to control with anti-epilepsy drugs (AED's) and most patients respond to monotherapy. Valproic acid is the most effective medication and drug of choice for treatment of JME. It is a broad spectrum medication and treats all seizure types of JME. Its use requires a great deal of caution in women of childbearing age given its well known teratogenic potential. Other treatment options include levetiracetam, lamotrigine, topiramate, and zonisamide. Lamotrigine can lead to a worsening in myoclonic seizures but is still widely used for the treatment of JME as it controls the other seizure types. If only absence seizures are present, ethosuximide can be a therapy choice. Clonazepam is effective against myoclonic jerks. Contraindicated agents include carbamazepine, oxcarbazepine, phenytoin (sodium channel blocking agents) given their potential to exacerbate myoclonic and absence seizures. But, they can be useful for the treatment of GTC seizures in JME. Other medications to avoid include vigabatrin, tiagabine, gabapentin, pregabalin, primidone. JME is intractable in only a few patients, and combination therapy with or without vagus nerve stimulation (VNS) is an option in such cases.
Many other epilepsy syndromes have similar features and resemble JME at various stages of their progression. Differential diagnosis includes childhood or juvenile absence epilepsy, eyelid myoclonia with absences, progressive myoclonic epilepsy, photosensitive occipital epilepsy, epilepsy with grand mal seizures upon awakening, hypnogogic myoclonus (hypnic jerk), non-epileptic seizures.
Seizures are usually well controlled with medications in a great majority of patients with JME and generally improve after the fourth decade of life. But, JME requires lifelong treatment (even after a long seizure-free interval), as the chances of relapse are high if medications are discontinued.
While JME management is chiefly under a neurologist, the follow up is usually under the primary caregiver or nurse practitioner. The key to prevention of seizures is patient education.
Avoidance of precipitating factors/triggers should be a strong emphasis. These include avoiding alcohol use, fatigue, stress, sleep deprivation, flashing lights in any form, medication non-compliance, hunger, extremes of temperature, drug use. Patients should also be advised/educated with precautions regarding driving, operating heavy machinery, swimming, avoiding heights/being near fire all alone. The treatment is usually life long (even after a long seizure-free interval), as the chances of relapse are high if medications are discontinued. As with any epilepsy syndrome, risks versus benefits of medications during pregnancy should be a point of discussion in details with the patient.
We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.
This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.
Click Your Answer Below
Would you like to access teaching points and more information on this topic?
Click Your Answer Below
Would you like to access teaching points and more information on this topic?
|Martínez-Juárez IE,Alonso ME,Medina MT,Durón RM,Bailey JN,López-Ruiz M,Ramos-Ramírez R,León L,Pineda G,Castroviejo IP,Silva R,Mija L,Perez-Gosiengfiao K,Machado-Salas J,Delgado-Escueta AV, Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up. Brain : a journal of neurology. 2006 May [PubMed]|
|Baykan B,Altindag EA,Bebek N,Ozturk AY,Aslantas B,Gurses C,Baral-Kulaksizoglu I,Gokyigit A, Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy. Neurology. 2008 May 27 [PubMed]|
|Panayiotopoulos CP,Obeid T,Tahan AR, Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia. 1994 Mar-Apr [PubMed]|
|Hauser WA, The prevalence and incidence of convulsive disorders in children. Epilepsia. 1994 [PubMed]|
|Janz D, Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta neurologica Scandinavica. 1985 Nov [PubMed]|
|Canevini MP,Mai R,Di Marco C,Bertin C,Minotti L,Pontrelli V,Saltarelli A,Canger R, Juvenile myoclonic epilepsy of Janz: clinical observations in 60 patients. Seizure. 1992 Dec [PubMed]|
|Buraei Z,Yang J, The ß subunit of voltage-gated Ca2 channels. Physiological reviews. 2010 Oct [PubMed]|
|Delgado-Escueta AV,Koeleman BP,Bailey JN,Medina MT,Durón RM, The quest for juvenile myoclonic epilepsy genes. Epilepsy [PubMed]|
|Liu M,Concha L,Beaulieu C,Gross DW, Distinct white matter abnormalities in different idiopathic generalized epilepsy syndromes. Epilepsia. 2011 Dec [PubMed]|
|Tae WS,Kim SH,Joo EY,Han SJ,Kim IY,Kim SI,Lee JM,Hong SB, Cortical thickness abnormality in juvenile myoclonic epilepsy. Journal of neurology. 2008 Apr [PubMed]|
|Mory SB,Betting LE,Fernandes PT,Lopes-Cendes I,Guerreiro MM,Guerreiro CA,Cendes F,Li LM, Structural abnormalities of the thalamus in juvenile myoclonic epilepsy. Epilepsy [PubMed]|
|Vijai J,Cherian PJ,Stlaja PN,Anand A,Radhakrishnan K, Clinical characteristics of a South Indian cohort of juvenile myoclonic epilepsy probands. Seizure. 2003 Oct [PubMed]|
|Jayalakshmi SS,Srinivasa Rao B,Sailaja S, Focal clinical and electroencephalographic features in patients with juvenile myoclonic epilepsy. Acta neurologica Scandinavica. 2010 Aug [PubMed]|
|Murthy JM,Rao CM,Meena AK, Clinical observations of juvenile myoclonic epilepsy in 131 patients: a study in South India. Seizure. 1998 Feb [PubMed]|
|Trinka E,Kienpointner G,Unterberger I,Luef G,Bauer G,Doering LB,Doering S, Psychiatric comorbidity in juvenile myoclonic epilepsy. Epilepsia. 2006 Dec [PubMed]|
|Moschetta S,Fiore LA,Fuentes D,Gois J,Valente KD, Personality traits in patients with juvenile myoclonic epilepsy. Epilepsy [PubMed]|
|Somayajula S,Vooturi S,Jayalakshmi S, Psychiatric disorders among 165 patients with juvenile myoclonic epilepsy in India and association with clinical and sociodemographic variables. Epilepsy [PubMed]|
|Chowdhury A,Brodie MJ, Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate. Epilepsy research. 2016 Jan [PubMed]|
|Tomson T,Battino D,Perucca E, Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. The Lancet. Neurology. 2016 Feb [PubMed]|
|Knott C,Panayiotopoulos CP, Carbamazepine in the treatment of generalised tonic clonic seizures in juvenile myoclonic epilepsy. Journal of neurology, neurosurgery, and psychiatry. 1994 Apr [PubMed]|
|Bodenstein-Sachar H,Gandelman-Marton R,Ben-Zeev B,Chapman J,Blatt I, Outcome of lamotrigine treatment in juvenile myoclonic epilepsy. Acta neurologica Scandinavica. 2011 Jul [PubMed]|
|Biraben A,Allain H,Scarabin JM,Schück S,Edan G, Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology. 2000 Dec 12 [PubMed]|
|Kothare SV,Valencia I,Khurana DS,Hardison H,Melvin JJ,Legido A, Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic disorders : international epilepsy journal with videotape. 2004 Dec [PubMed]|
|Mantoan L,Walker M, Treatment options in juvenile myoclonic epilepsy. Current treatment options in neurology. 2011 Aug [PubMed]|
|Verrotti A,Cerminara C,Coppola G,Franzoni E,Parisi P,Iannetti P,Aloisi P,Tozzi E,Cusmai R,Vigevano F,Chiarelli F,Curatolo P, Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Developmental medicine and child neurology. 2008 Jan [PubMed]|
|Levisohn PM,Holland KD, Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy [PubMed]|
|Liu J,Wang LN,Wang YP, Topiramate monotherapy for juvenile myoclonic epilepsy. The Cochrane database of systematic reviews. 2015 Dec 23 [PubMed]|
|Kostov H,Larsson PG,Røste GK, Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy? Acta neurologica Scandinavica. Supplementum. 2007 [PubMed]|
|Baise-Zung C,Guilhoto LM,Grossmann RM, Juvenile myoclonic epilepsy: non-classic electroencephalographical presentation in adult patients. European journal of neurology. 2006 Feb [PubMed]|
|Dhanuka AK,Jain BK,Daljit S,Maheshwari D, Juvenile myoclonic epilepsy: a clinical and sleep EEG study. Seizure. 2001 Jul [PubMed]|
|Létourneau K,Cieuta-Walti C,Deacon C, Epileptiform asymetries and treatment response in juvenile myoclonic epilepsy. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2010 Nov [PubMed]|
|Hrachovy RA,Frost JD Jr, The EEG in selected generalized seizures. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society. 2006 Aug [PubMed]|
|Anderson J,Hamandi K, Understanding juvenile myoclonic epilepsy: contributions from neuroimaging. Epilepsy research. 2011 May [PubMed]|
The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Neurology-Epilepsy. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.
StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Neurology-Epilepsy, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Neurology-Epilepsy, you will already be prepared.
Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Neurology-Epilepsy. When it is time for the Neurology-Epilepsy board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Neurology-Epilepsy.